Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143091 · ClinicalTrials.gov registry record · Phase 2
Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00143091 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 200 participants.
The verdict
NCT00143091, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.
Interventions
- DRUG Placebo
- DRUG Sertraline
- DRUG CP-316,311
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-04 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143091
The ClinicalTrials.gov registry entry for NCT00143091 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00143091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143091 about?
NCT00143091 is a clinical study titled "Multicentre Trial to Evaluate the Safety and Efficacy of CP-316,311 in Major Depressive Disorder". A six week, fixed dose, double-blind, double-dummy, placebo, and active controlled, multicentre trial to evaluate the safety and efficacy of CP-316,311 in outpatients with major depressive disorder.
What is the current status of trial NCT00143091?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2005-04. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00143091?
The interventions under investigation include: Placebo (DRUG), Sertraline (DRUG), CP-316,311 (DRUG).
Who is sponsoring clinical trial NCT00143091?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.